EvoEndo gets AGA investment for unsedated transnasal endoscopy platforms

EvoEndo has landed an investment from GI Opportunity Fund 1, a new venture capital fund of the American Gastroenterological Association (AGA) for its unsedated transnasal endoscopy platforms.

Further details of the investment have not been disclosed by the US-based medical device company.

Founded in 2017, EvoEndo develops sterile single-use, flexible unsedated transnasal endoscopes for assessing and diagnosing a wide range of upper gastrointestinal (GI) conditions in a clinical setting.

Michael L Kochman — AGA GI Opportunity Fund Fund Manager and Advisor said: “AGA is proud to support EvoEndo and its innovative technology that has the potential to improve care, save time, resources, and cost for hospitals and the GI community at large.”

The EvoEndo Single-Use Endoscopy System combines sterile, single-use, flexible endoscopes, a portable video controller, and Comfort Kit.

The EvoEndo Controller is intended for use with an EvoEndo Endoscope for endoscopic diagnosis, treatment, and video observation.

The take-home EvoEndo Comfort Kit includes virtual reality goggles for patient distraction during the unsedated transnasal endoscopy procedure and is not part of the cleared EvoEndo System.

Jonathan T Hartmann – EvoEndo CEO said: “We are grateful for the support of the AGA, which is a testament to our ongoing commitment to improving GI outcomes with our technology.

“The AGA has always been at the forefront of improving GI care – our team could not be more excited that they have recognized EvoEndo, and we look forward to continuing to expand adoption of our technology to the GI community, its physicians, and their patients.”

In February 2022, the EvoEndo Single-Use Endoscopy System secured 510(k) clearance from the US Food and Drug Administration (FDA).

The EvoEndo Model LE Gastroscope is a sterile, single-use device for the visualization of the upper digestive tract in adults and pediatric patients over the age of five.